Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.

Health technology assessment (Winchester, England)

Volumn 15 Suppl 1, Issue , 2011, Pages 33-42

  Norman, G ^a   Rice, S ^b   Spackman, E ^b   Stirk, L ^b   Danso Appiah, A ^b   Suh, D ^b   Palmer, S ^b   Eastwood, A ^b  

^a UNIVERSITY OF YORK   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; DEOXYCYTIDINE; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ADENOCARCINOMA; COST BENEFIT ANALYSIS; ECONOMICS; ESOPHAGUS TUMOR; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; META ANALYSIS (TOPIC); METASTASIS; MULTICENTER STUDY (TOPIC); PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMACH TUMOR;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CISPLATIN; CLINICAL TRIALS, PHASE III AS TOPIC; COST-BENEFIT ANALYSIS; DEOXYCYTIDINE; EPIRUBICIN; ESOPHAGEAL NEOPLASMS; FLUOROURACIL; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; META-ANALYSIS AS TOPIC; MULTICENTER STUDIES AS TOPIC; NEOPLASM METASTASIS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

MLCS; MLOWN;

EID: 84891723797     PISSN: None     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta15suppl1/04     Document Type: Review

References (0)